Financial giants have made a conspicuous bearish move on Humacyte. Our analysis of options history for Humacyte (NASDAQ:HUMA) revealed 9 unusual trades. Delving into the details, we found 11% of ...

Humacyte, Inc. (NASDAQ:HUMA – Free Report) – Cantor Fitzgerald upped their FY2024 EPS estimates for Humacyte in a research note issued on Wednesday, January 15th. Cantor Fitzgerald analyst K.

https://www.tipranks.com/news/the-fly/biocryst-price-target-raised-to-12-from-10-at-evercore-isi Benchmark analyst Bruce Jackson raised the firm’s price target on ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed to replace a patient’s damaged artery following traumatic injuries ...

Humacyte stock has dropped 46% since July, mainly due to FDA review delays and mixed Phase 3 trial results for their ATEVs in hemodialysis. Despite FDA approval of Symvess for vascular trauma, its ...

DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered ...

Humacyte (HUMA) announced an update of plans for the commercial launch of Symvess for extremity arterial injury. Humacyte is responding to requests for quotations from hospitals and has initiated ...

LOS ANGELES, Jan. 17, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Humacyte, Inc. ("HUMA" or "the Company") (NASDAQ: HUMA) for violations of the ...

Shares of Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) fell 3% during mid-day trading on Tuesday . The company traded as low as $4.43 and last traded at $4.51. 3,525,988 shares changed hands ...

Benchmark analyst Bruce Jackson raised the firm’s price target on Humacyte (HUMA) to $17 from $15 and keeps a Buy rating on the shares. Humacyte announced it received full FDA approval for ...